These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15058791)

  • 1. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
    Salek MS; Finlay AY; Lewis JJ; Sumner MI
    Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
    Touw CR; Hakkaart-Van Roijen L; Verboom P; Paul C; Rutten FF; Finlay AY
    Br J Dermatol; 2001 May; 144(5):967-72. PubMed ID: 11359382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
    Ito T; Furukawa F; Iwatsuki K; Matsue H; Shimada S; Takigawa M; Tokura Y
    J Dermatol; 2014 May; 41(5):377-81. PubMed ID: 24628433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
    Berth-Jones J; Henderson CA; Munro CS; Rogers S; Chalmers RJ; Boffa MJ; Norris PG; Friedmann PS; Graham-Brown RA; Dowd PM; Marks R; Sumner MJ
    Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life.
    Karamata VV; Gandhi AM; Patel PP; Sutaria A; Desai MK
    Indian J Pharmacol; 2017; 49(1):84-88. PubMed ID: 28458428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
    Ho VC; Griffiths CE; Albrecht G; Vanaclocha F; León-Dorantes G; Atakan N; Reitamo S; Ohannesson A; Mørk NJ; Clarke P; Pfister P; Paul C
    Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
    Pedraz J; Daudén E; Delgado-Jiménez Y; García-Río I; García-Díez A
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):702-6. PubMed ID: 16836499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
    Reitamo S; Spuls P; Sassolas B; Lahfa M; Claudy A; Griffiths CE;
    Br J Dermatol; 2001 Sep; 145(3):438-45. PubMed ID: 11531834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin.
    Gulliver WP; Murphy GF; Hannaford VA; Primmett DR
    Br J Dermatol; 1996 Sep; 135 Suppl 48():35-9. PubMed ID: 8881903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
    Peluso AM; Bardazzi F; Tosti A; Varotti C
    Acta Derm Venereol Suppl (Stockh); 1994; 186():90-1. PubMed ID: 8073851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
    Shintani Y; Kaneko N; Furuhashi T; Saito C; Morita A
    J Dermatol; 2011 Oct; 38(10):966-72. PubMed ID: 21545506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
    Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.